<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>PeptideScanner evidence for Carfilzomib</title><link>https://peptidescanner.com/peptides/carfilzomib/</link><description>Versioned, source-linked PeptideScanner evidence objects for Carfilzomib. Selected coverage; not medical advice.</description><language>en-us</language><atom:link href="https://peptidescanner.com/feeds/peptides/carfilzomib.xml" rel="self" type="application/rss+xml"/><item><title>ClinicalTrials.gov record NCT03606577</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03606577-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03606577-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03606577-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-11-12. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-17</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT06152575</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct06152575-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct06152575-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct06152575-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-11-12. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-17</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT07555938</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07555938-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct07555938-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07555938-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-11-10. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-17</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT07715903</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct07715903-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct07715903-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07715903-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-11-16. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-17</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application ANDA209330</title><link>https://peptidescanner.com/stories/fda-drugs-anda209330/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-anda209330:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209330-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2021-06-11. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application ANDA209422</title><link>https://peptidescanner.com/stories/fda-drugs-anda209422/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-anda209422:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209422-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2019-09-09. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application ANDA209425</title><link>https://peptidescanner.com/stories/fda-drugs-anda209425/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-anda209425:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209425-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2020-03-16. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application ANDA209526</title><link>https://peptidescanner.com/stories/fda-drugs-anda209526/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-anda209526:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209526-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2026-07-20. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application ANDA211185</title><link>https://peptidescanner.com/stories/fda-drugs-anda211185/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-anda211185:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda211185-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2020-03-20. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Drugs@FDA application NDA202714</title><link>https://peptidescanner.com/stories/fda-drugs-nda202714/</link><guid isPermaLink="false">urn:peptidescanner:story:fda-drugs-nda202714:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-nda202714-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2012-07-20. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Federal Register notice 2012-10154</title><link>https://peptidescanner.com/stories/federal-register-2012-10154/</link><guid isPermaLink="false">urn:peptidescanner:story:federal-register-2012-10154:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2012-10154-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2012-04-27. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>Federal Register notice 2014-11175</title><link>https://peptidescanner.com/stories/federal-register-2014-11175/</link><guid isPermaLink="false">urn:peptidescanner:story:federal-register-2014-11175:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2014-11175-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Regulatory; date in source 2014-05-15. PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.</description><dc:date>2026-11-17</dc:date><category>Regulatory</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01080391</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01080391-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01080391-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01080391-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2022-09-21. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01302392</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01302392-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01302392-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01302392-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2017-05-02. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01559935</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01559935-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01559935-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01559935-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-09-29. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01568866</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01568866-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01568866-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01568866-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2022-11-14. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01572480</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01572480-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01572480-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01572480-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-03-10. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01813227</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01813227-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01813227-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01813227-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-04-03. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01816971</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01816971-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01816971-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01816971-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-04-21. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT01818752</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct01818752-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct01818752-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01818752-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2019-08-26. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT02412878</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct02412878-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct02412878-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02412878-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2022-09-23. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT02773030</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct02773030-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct02773030-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02773030-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-03-20. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT02937571</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct02937571-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct02937571-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02937571-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2025-11-20. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT02969837</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct02969837-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct02969837-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02969837-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-01-16. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03029234</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03029234-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03029234-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03029234-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2022-05-25. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03158688</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03158688-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03158688-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03158688-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2025-05-09. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03275285</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03275285-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03275285-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03275285-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-02-09. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03290950</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03290950-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03290950-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03290950-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-05-29. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03412565</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03412565-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03412565-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03412565-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2025-04-29. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03416374</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03416374-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03416374-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03416374-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2022-09-27. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03859427</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03859427-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03859427-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03859427-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2024-08-13. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT03934684</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct03934684-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct03934684-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03934684-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-05-11. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT04191616</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct04191616-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct04191616-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04191616-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2025-09-04. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT04430894</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct04430894-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct04430894-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04430894-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-10-06. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT04756401</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct04756401-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct04756401-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04756401-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-09-15. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT04925193</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct04925193-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct04925193-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04925193-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-10-02. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>ClinicalTrials.gov record NCT05497804</title><link>https://peptidescanner.com/stories/clinicaltrials-gov-nct05497804-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:clinicaltrials-gov-nct05497804-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct05497804-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Clinical trials; date in source 2026-11-02. PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.</description><dc:date>2026-11-16</dc:date><category>Clinical trials</category><category>Lifecycle state: current</category></item><item><title>Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.</title><link>https://peptidescanner.com/stories/pubmed-pmid-34647444-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-34647444-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34647444-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-09-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…</title><link>https://peptidescanner.com/stories/pubmed-pmid-34774221-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-34774221-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34774221-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2022-01-10. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.</title><link>https://peptidescanner.com/stories/pubmed-pmid-35578151-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-35578151-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-35578151-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-10-29. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.</title><link>https://peptidescanner.com/stories/pubmed-pmid-36073950-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36073950-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36073950-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.</title><link>https://peptidescanner.com/stories/pubmed-pmid-36372355-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36372355-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36372355-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.</title><link>https://peptidescanner.com/stories/pubmed-pmid-36375132-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36375132-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36375132-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…</title><link>https://peptidescanner.com/stories/pubmed-pmid-36529145-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36529145-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36529145-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-11-09. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…</title><link>https://peptidescanner.com/stories/pubmed-pmid-36642080-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36642080-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36642080-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.</title><link>https://peptidescanner.com/stories/pubmed-pmid-36763537-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-36763537-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36763537-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.</title><link>https://peptidescanner.com/stories/pubmed-pmid-37479547-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-37479547-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37479547-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.</title><link>https://peptidescanner.com/stories/pubmed-pmid-37584290-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-37584290-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37584290-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2024-10-23. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…</title><link>https://peptidescanner.com/stories/pubmed-pmid-37632592-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-37632592-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37632592-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…</title><link>https://peptidescanner.com/stories/pubmed-pmid-37691005-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-37691005-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37691005-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-01-27. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.</title><link>https://peptidescanner.com/stories/pubmed-pmid-37717583-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-37717583-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37717583-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-03-24. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…</title><link>https://peptidescanner.com/stories/pubmed-pmid-38747414-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-38747414-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38747414-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2024-09-14. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.</title><link>https://peptidescanner.com/stories/pubmed-pmid-38811560-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-38811560-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38811560-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2024-11-07. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.</title><link>https://peptidescanner.com/stories/pubmed-pmid-38938122-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-38938122-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38938122-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2025-01-30. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.</title><link>https://peptidescanner.com/stories/pubmed-pmid-39576965-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-39576965-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39576965-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2025-06-03. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.</title><link>https://peptidescanner.com/stories/pubmed-pmid-39638553-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-39638553-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39638553-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2025-06-05. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.</title><link>https://peptidescanner.com/stories/pubmed-pmid-40213696-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-40213696-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40213696-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2025-04-12. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.</title><link>https://peptidescanner.com/stories/pubmed-pmid-40397818-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-40397818-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40397818-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-11-13. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.</title><link>https://peptidescanner.com/stories/pubmed-pmid-40672881-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-40672881-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40672881-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2025-09-06. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.</title><link>https://peptidescanner.com/stories/pubmed-pmid-41134506-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-41134506-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41134506-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-10-09. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.</title><link>https://peptidescanner.com/stories/pubmed-pmid-41719502-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-41719502-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41719502-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-09-26. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item><item><title>Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.</title><link>https://peptidescanner.com/stories/pubmed-pmid-41942646-carfilzomib/</link><guid isPermaLink="false">urn:peptidescanner:story:pubmed-pmid-41942646-carfilzomib:v1:current</guid><atom:link href="https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41942646-carfilzomib-v1" rel="alternate" type="application/json"/><description>Lifecycle state current; Literature metadata; date in source 2026-08-13. PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article&apos;s findings.</description><dc:date>2026-11-16</dc:date><category>Literature metadata</category><category>Lifecycle state: current</category></item></channel></rss>
